Reuters logo
BRIEF-Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2
2016年11月21日 / 中午11点42分 / 10 个月前

BRIEF-Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2

Nov 21 (Reuters) - Immunocellular Therapeutics Ltd

* Immunocellular Therapeutics reports updated immune monitoring data from ICT-107 phase 2 trial in newly diagnosed glioblastoma at the society for neuro-oncology annual meeting 2016

* Immunocellular therapeutics ltd - Data from phase 2 trial indicated a survival advantage in ICT-107 treated group compared to control group

* Immunocellular therapeutics - In current ongoing phase 3 registration trial of ICT-107, co plans to perform immuno-monitoring to support trial

* Immunocellular Therapeutics - Phase 2 trial data also showed association between immune response, survival, especially in HLA-A2 positive patients

* Immunocellular Therapeutics- Updated immune response data from phase 2 trial showed ICT-107 resulted in development of measurable anti-tumor T cell response

* Immunocellular Therapeutics - Updated immune response data showed ICT-107 resulted in development of measurable anti-tumor T cell response in some patients Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below